top of page

Lillia in focus

News, research, and thought leadership at the intersection of AI

and chronic care

LilliaGradient_LinkedInCover (1).png

TIME names Lillia a top healthtech company

LilliaGradient_LinkedInCover (1).png

Lillia has been recognized by TIME among the World’s Top HealthTech Companies of 2025

Ranked in the AI & Data Analytics category with a ‘Very High’ performance indicator, this milestone highlights our global impact at the intersection of AI-driven insights and human-centered care

LilliaGradient_LinkedInCover (1).png

Lillia secures $1.7M grant to advance AI-powered chronic care

LilliaGradient_LinkedInCover (1).png

Lillia unveils its AI platform and digital twin technology to transform chronic disease management

Backed by a $1.7M QRDI Council grant and partnerships with 20 institutional clients, Lillia has already supported over 40,000 individuals across GCC and India, paving the way for global expansion and precision, AI-driven care

LilliaGradient_LinkedInCover (1).png

PHCC, Qatar: Largest diabetes management study in GCC

​

Published by American Diabetes Association (ADA) cohort of 633 patients across 27 Primary Health Care Corporation (PHCC) clinics

LilliaGradient_LinkedInCover (1).png

Outcome highlights

  • Reduction in HbA1c:
    0.91% reduction for patients with initial HbA1c ≥ 8

  • Reduction in blood pressure:
    7.84% reduction in systolic blood pressure for patients with initial BP ≥ 130/80

  • Reduction in cholesterol:
    0.81 mmol/L reduction in total cholesterol for patients with cholesterol levels ≥ 5.18 mmol/L

  • Reduction in weight:
    0.72% reduction in BMI for patients with initial BMI ≥ 25

LilliaGradient_LinkedInCover (1).png

India: Large-scale diabetes management study

​

Published by American Diabetes Association (ADA) cohort of 808 patients across 50 cities in India

LilliaGradient_LinkedInCover (1).png

Outcome highlights

  • Reduction in HbA1c:
    1.10% reduction for 808 patients

​

  • Reduction in HbA1c (uncontrolled
    diabetes):
    2.18% reduction for patients with
    initial HbA1c ≥ 9

​

  • Increase in time in range (TIR):
    7.16% increase for patients with
    initial TIR of 40.3% ± 31%

LilliaGradient_LinkedInCover (1).png

Case Study: Leading clinic chain in India

​

Obesity and Diabetes Management Program

LilliaGradient_LinkedInCover (1).png

Outcome highlights

  • Reduction in HbA1c:
    1.40% average reduction

​

  • Reduction in BMI:
    3.35 average reduction for most compliant users

​

  • Reduction in weight:
    3.50kg average reduction

Media features

png-clipart-wamda-logo-brand-product-design-abu-dhabi-blue-company-removebg-preview.png

Our approach

Chronic conditions drive most healthcare costs, yet care delivery remains fragmented and reactive.

 

Lillia transforms this model, connecting data, devices, and human expertise through AI to enable proactive, continuous, and personalized care at scale.

01

Evidence of improved adherence and outcomes

02

Expertise in AI-powered, digital end-to-end chronic care workflows 

03

Trusted by providers and payers globally

The Impact

bottom of page